Halozyme Therapeutics Inc. diskutieren
Halozyme Therapeutics Inc.
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
60,20 €
5,65 %
Halozyme Therapeutics (HALO) had its price target lowered by Morgan Stanley from $96.00 to $93.00. They now have an "overweight" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (HALO) had its "buy" rating reaffirmed by UBS Group AG.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (HALO) had its "buy" rating reaffirmed by Benchmark Co..
Ratings data for HALO provided by MarketBeat


Neueste Beiträge
Roth_Mkm in International Business Machines Corp diskutieren